NDA 206679 · Salerno Pharms
Flolipid
Simvastatin · Oral
Last checked: Nov 20, 2026Latest source record: Sep 25, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 21, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
616
177 Phase 3, 25 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 21, 2016 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLetter
2 products under this application
- FLOLIPID · SIMVASTATIN 40MG/5ML · SUSPENSION, ORAL · Prescription
- FLOLIPID · SIMVASTATIN 20MG/5ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Simvastatin" as an intervention, any sponsor and status, largest first.
- Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) TrialPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT06856772 · 42,000 participants (planned) · Start Feb 28, 2025 · Primary completion Mar 28, 2028
Drug: Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) · For: Cardiovascular Diseases (CVD); Drug Effect; Atherosclerosis Cardiovascular Disease
Sites: Hellerup, Denmark
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVEPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00461630 · 25,673 participants · Start Jan 2007 · Primary completion Oct 2012
Drug: ER niacin/laropiprant; simvastatin and 1 more · For: Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus and 1 more
Sites: Oxford, United Kingdom
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00202878 · 18,144 participants · Start Oct 17, 2005 · Primary completion Sep 18, 2014
Drug: ezetimibe/simvastatin; simvastatin and 2 more · For: Hypercholesterolemia; Myocardial Infarction
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Study of the Effectiveness of Additional Reductions in Cholesterol and HomocysteinePivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00124072 · 12,064 participants · Start Jul 1998 · Primary completion May 2008
Drug: Simvastatin 20 mg daily; Simvastatin 80 mg daily and 1 more · For: Cardiovascular Disease
Sites: Oxford, United Kingdom
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Study of Heart and Renal ProtectionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00125593 · 9,438 participants · Start Jun 2003 · Primary completion Aug 2010
Drug: Simvastatin 20 mg; Ezetimibe 10mg and 1 more · For: Kidney Disease, Chronic
Sites: Oxford, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Flolipid (Simvastatin)
2024 spending
$3K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$1.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $7,953 |
| 2023 | $5,400 |
| 2024 | $3,309 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
· Lancet 1994 · Clinical Trial, Randomized Controlled Trial
- Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M, Ambegaonkar B, Baxter CA, et al. · Clin Res Cardiol 2019 · Systematic Review, Network Meta-Analysis
- Simvastatin in Critically Ill Patients with Covid-19.
Hills TE, Lorenzi E, Berry LR, et al. · N Engl J Med 2023 · Multicenter Study, Randomized Controlled Trial
- Statins for multiple sclerosis.
Wang J, Xiao Y, Luo M, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity: A Randomized Clinical Trial.
Otte C, Chae WR, Dogan DY, et al. · JAMA Psychiatry 2025 · Randomized Controlled Trial, Multicenter Study
Sponsor: Salerno Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.